JW (Cayman) Therapeutics Co. Ltd
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JWCTF research report →
About the company
JW (Cayman) Therapeutics Co. Ltd is a biopharmaceutical entity currently in the clinical development phase, dedicated to the discovery, manufacturing, and commercialization of advanced cell-based immunotherapeutic solutions. Its core mission is to combat both hematological cancers (blood cancers) and various solid tumors.
- CEO
- Min Liu
- IPO
- 2021
- Employees
- 281
- HQ
- Shanghai, CN
Price Chart
- Market Cap
- $97.08M
- P/E
- -1.23
- P/S
- 2.41
- P/B
- 1.22
- EV/EBITDA
- -2.00
- Div Yield
- 0.00%
- Gross Margin
- 43.15%
- Op Margin
- -105.50%
- Net Margin
- -196.12%
- ROE
- -75.15%
- ROIC
- -36.15%
- Revenue
- $276.33M · 74.65%
- Net Income
- $-540,962,213 · 8.41%
- EPS
- $-1.33 · 6.99%
- Op Income
- $-241,728,741
- FCF YoY
- 77.51%
- 52W High
- $0.66
- 52W Low
- $0.23
- 50D MA
- $0.26
- 200D MA
- $0.34
- Beta
- 1.91
- Avg Volume
- 6.46K
Get TickerSpark's AI analysis on JWCTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our JWCTF coverage
Recent articles, reports, and earnings notes.
No research on JWCTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate JWCTF report →Similar companies
Peers in the same neighborhood.